Skip to main content
. 2014 Jul 8;2(6):935–944. doi: 10.3892/mco.2014.338

Figure 4.

Figure 4

Interaction surface built using the estimated combination index (CI) for each combination experiment comprising the CIGB-300 peptide and the chemotherapeutic drugs (A) paclitaxel, (B) cisplatin, (C) doxorubicin, or (D) 5-fluorouracil (5-FU) in the NCI-H125 lung cancer cell line. The graphics show the fraction affected (Fa) by each combination across such an interaction surface and the concentrations of each particular drug in the combinations.